Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.

In the general population, ovarian cancer risk is inversely associated with oral contraceptive use, tubal ligation, and childbearing. Among carriers of BRCA1 gene mutations, the data are conflicting. The authors identified women diagnosed with incident invasive epithelial ovarian cancer in the San Francisco Bay Area of California from March 1997 through July 2001. They compared the contraceptive and reproductive histories of 36 carrier cases and 381 noncarrier cases with those of 568 controls identified by random digit dialing who were frequency matched to cases on age and race/ethnicity. In both carriers and noncarriers, reduced risk was associated with ever use of oral contraceptives (odds ratio = 0.54 (95% confidence interval (CI): 0.26, 1.13) for carriers and 0.55 (95% CI: 0.41, 0.73) for noncarriers), duration of oral contraceptive use (risk reduction per year = 13% (p = 0.01) for carriers and 6% (p < 0.001) for noncarriers), history of tubal ligation (odds ratio = 0.68 (95% CI: 0.25, 1.90) for carriers and 0.65 (95% CI: 0.45, 0.95) for noncarriers), and increasing parity (risk reduction per childbirth = 16% (p = 0.26) for carriers and 24% (p < 0.001) for noncarriers). These data suggest that BRCA1 mutation carriers and noncarriers have similar risk reductions associated with oral contraceptive use, tubal ligation, and parity.

[1]  R. Dicioccio,et al.  A polymorphism in intron 2 of the TP53 gene. , 2008, Clinical genetics.

[2]  P. Hartge,et al.  Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. , 2003, Journal of the National Cancer Institute.

[3]  D. Fishman,et al.  Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States) , 2003, Cancer Causes & Control.

[4]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[5]  J. Boyd,et al.  Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer , 2002, Current opinion in obstetrics & gynecology.

[6]  J. Cerhan,et al.  Association of Parity and Ovarian Cancer Risk by Family History of Breast or Ovarian Cancer in a Population-Based Study of Postmenopausal Women , 2002, Epidemiology.

[7]  S Wacholder,et al.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[8]  C. Isaacs,et al.  Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study , 2001, The Lancet.

[9]  C. la Vecchia,et al.  Reproductive and hormonal factors and ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[11]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[12]  I. Runnebaum,et al.  Epidemiological and molecular aspects of ovarian cancer risk , 2001, Journal of Cancer Research and Clinical Oncology.

[13]  D. Grabrick,et al.  Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. , 2000, JAMA.

[14]  C. la Vecchia,et al.  Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. , 2000, International journal of epidemiology.

[15]  B. Werness,et al.  Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. , 1999, Cancer genetics and cytogenetics.

[16]  S. Nilsson,et al.  Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence , 1998, Clinical endocrinology.

[17]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[18]  B. Godard,et al.  Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. , 1998, American journal of obstetrics and gynecology.

[19]  L. Le Marchand,et al.  A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[21]  B. Henderson,et al.  Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? , 1997, Cancer research.

[22]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[23]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[24]  J. Boyd,et al.  Hereditary ovarian cancer: molecular genetics and clinical implications. , 1997, Gynecologic oncology.

[25]  L. Cannon-Albright,et al.  Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.

[26]  W. Willett,et al.  Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study , 1993 .

[27]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[28]  J Halpern,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[29]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Thompson,et al.  Familial ovarian cancer: a population-based case-control study. , 1988, American journal of epidemiology.

[31]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[32]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[33]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[34]  N. Breslow,et al.  The analysis of case-control studies , 1980 .